不确定期慢性HBV感染者应个体化治疗

蒋莹莹; 任姗; 陈新月; 郑素军

doi:10.3969/j.issn.1001-5256.2021.11.009

不确定期慢性HBV感染者应个体化治疗

DOI: 10.3969/j.issn.1001-5256.2021.11.009

蒋莹莹^a,
任姗^b,
陈新月^b, ,,
郑素军^b, ,

a.
首都医科大学附属北京佑安医院肝病消化中心，北京 100069
b.
首都医科大学附属北京佑安医院肝病一科，北京 100069

基金项目:

国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治” (2017ZX10302201-004);

国家科技重大专项“艾滋病和病毒性肝炎等重大传染病防治” (2017ZX10202203-006);

北京市医院管理中心重点医学专业发展计划(扬帆计划)资助 (ZYLX202125);

首都卫生发展科研专项项目 (2020-1-2181)

详细信息

通信作者:
陈新月，chenxydoc@163.com

郑素军，zhengsujun003@126.com

中图分类号: R512.62
计量
- 文章访问数: 418
- HTML全文浏览量: 61
- PDF下载量: 80
- 被引次数: 0
出版历程
- 收稿日期: 2021-09-16
- 录用日期: 2021-09-16
- 出版日期: 2021-11-20

Patients in the indeterminate phase of chronic hepatitis B virus infection should be treated

a.
Department of Gastroenterology and Hepatology, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China
b.
Department of Liver Disease, Beijing YouAn Hospital, Capital Medical University, Beijing 100069, China

Research funding:

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Preventon and Treatment" (2017ZX10302201-004);

National Science and Technology Key Project on "Major Infectious Diseases such as HIV/AIDS, Viral Hepatitis Preventon and Treatment" (2017ZX10202203-006);

Beijing Municipal Administration of Hospitals Clinical Medicine Development of Special Funding Support (ZYLX202125);

Capital Health Research and Development Projects (2020-1-2181)

摘要

- 乙型肝炎病毒 /
- 乙型肝炎，慢性 /
- 不确定期 /
- 治疗学
- Hepatitis B Virus /
- Hepatitis B, Chronic /
- Indeterminate Phrase /
- Therapeutic

HTML全文

参考文献(10)

[1]	Polaris Observatory Collaborators. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: A modelling study[J]. Lancet Gastroenterol Hepatol, 2018, 3(6): 383-403. DOI: 10.1016/S2468-1253(18)30056-6.
[2]	Chinese Society of Infectious Diseases, Chinese Medical Association, Chinese Society of Hepatology, Chinese Medical Association. Guidelines for the prevention and treatment of chronic hepatitis B (version 2019)[J]. J Clin Hepatol, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007. 中华医学会感染病学分会, 中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J]. 临床肝胆病杂志, 2019, 35(12): 2648-2669. DOI: 10.3969/j.issn.1001-5256.2019.12.007.
[3]	HUANG DQ, LI X, LE MH, et al. Natural history and hepatocellular carcinoma risk in untreated chronic hepatitis B patients with indeterminate phase[J]. Clin Gastroenterol Hepatol, 2021. DOI: 10.1016/j.cgh.2021.01.019.[Onlineaheadofprint]
[4]	ZHANG JQ, LI MM, QI XS, et al. An excerpt of update on prevention, diagnosis, and treatment and of chronic hepatitis B: AASLD 2018 hepatitis B guidance[J]. J Clin Hepatol, 2018, 34(12): 2563-2567. DOI: 10.3969/j.issn.1001-5256.2018.12.011. 张晶巧, 李苗苗, 祁兴顺, 等. 《2018年美国肝病学会乙型肝炎指引声明意见: 慢性乙型肝炎的预防、诊断和治疗》摘译[J]. 临床肝胆病杂志, 2018, 34(12): 2563-2567. DOI: 10.3969/j.issn.1001-5256.2018.12.011.
[5]	YU YC, HOU JL. The highlights of EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection[J]. J Clin Hepatol, 2017, 33(6): 1017-1032. DOI: 10.3969/j.issn.1001-5256.2017.06.002. 于乐成, 侯金林. 2017年欧洲肝病学会临床实践指南: HBV感染的管理(精粹)[J]. 临床肝胆病杂志, 2017, 33(6): 1017-1032. DOI: 10.3969/j.issn.1001-5256.2017.06.002.
[6]	SARIN SK, KUMAR M, LAU GK, et al. Asian-Pacific clinical practice guidelines on the management of hepatitis B: A 2015 update[J]. Hepatol Int, 2016, 10(1): 1-98. DOI: 10.1007/s12072-015-9675-4.
[7]	YAO K, LIU J, WANG J, et al. Distribution and clinical characteristics of patients with chronic hepatitis B virus infection in the grey zone[J]. J Viral Hepat, 2021, 28(7): 1025-1033. DOI: 10.1111/jvh.13511.
[8]	HSU YN, PAN CQ, ABBASI A, et al. Clinical presentation and disease phases of chronic hepatitis B using conventional versus modified ALT criteria in Asian Americans[J]. Dig Dis Sci, 2014, 59(4): 865-871. DOI: 10.1007/s10620-014-3054-1.
[9]	CHOI GH, KIM GA, CHOI J, et al. High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation[J]. Aliment Pharmacol Ther, 2019, 50(2): 215-226. DOI: 10.1111/apt.15311.
[10]	BONACCI M, LENS S, MARIÑO Z, et al. Anti-viral therapy can be delayed or avoided in a significant proportion of HBeAg-negative Caucasian patients in the Grey Zone[J]. Aliment Pharmacol Ther, 2018, 47(10): 1397-1408. DOI: 10.1111/apt.14613.